




BATMAN

AIR MAX

SIAPA
DITANYA
DITANYA NOT MORE
AUSFA
PRATI
KIMMIL

MATERIAL SHOULD BE USED WITHIN SIX
MONTHS SHOULD BE KEPT AT

Cuántas generaciones se necesitan para salir de la pobreza



Fuente: OCDE

BBC

De Colombia para el mundo: Petro celebra primera vez que se exporta mango a Estados Unidos

Esta es la empresa en Magdalena que lo hizo posible y que ya exportaba a Europa y Canadá



Gustavo Petro resalta primera exportación de mango de azúcar a Estados Unidos Foto MinComercio (izquierda) y Europa Press Franz Ag (derecha) - 21 mayo 2023

Por Valeria Arias Suárez | 21 de mayo 2023 a las 12:25 hrs.

El [presidente Gustavo Petro se ha mantenido activo en redes sociales](#) durante este fin de semana de puente festivo en Colombia. Este domingo 21 de mayo celebró que Colombia por primera vez exportó mango de azúcar hacia Estados Unidos. Le contamos los detalles.

PUBLICIDAD


LO QUE DEBE SABER



La Alcaldía de Bogotá entregará 27 mil becas: conozca los sectores que...



Expotolima Corazón Cafetero: la feria que conectará el café tolimense con el mundo



Regreso a clases con tecnología innovadora para...

**Wadda
"F**K?"**











¿Para donde vamos?

Diciembre 20, 2021

COLOMBIA HACIA UNA SOCIEDAD DEL CONOCIMIENTO

Reflexiones y propuestas

Volumen 1

Documento
CONPES


CONSEJO NACIONAL DE POLÍTICA ECONÓMICA Y SOCIAL
REPÚBLICA DE COLOMBIA
DEPARTAMENTO NACIONAL DE PLANEACIÓN

4069




El futuro
es de todos

Gobierno
de Colombia



MISIÓN DE
SABIOS
COLOMBIA - 2019

- 
- Human Capital and Research (81st)
 - Creative Outputs (80th)
 - Institutions (78th)

Global Innovation Index (GII), 2023

F

¿Qué nos pasa?



La internacionalización de Colombia es precaria.

CONSEJO PRIVADO DE COMPETITIVIDAD, INFORME NACIONAL DE COMPETITIVIDAD 2022-2023







**LET'S GET
SEXY, BABY!**



+100%
patentes en
10 años













\$30 mil mill.

2 500 universidades

+300 mil

investigadores



UNIVERSITY OF
MICHIGAN



University of
Pittsburgh



Stanford
University



JOHNS HOPKINS
UNIVERSITY

Duke
UNIVERSITY

UCSF

University of California
San Francisco



Washington
University in St. Louis




Yale University



\$165 millones
40 empresas

Genesis Therapeutics secures \$200 million funding for clinical trials of AI-designed drugs


The company, which originated from Stanford University in 2019, has been focused on creating a deep learning platform called **GEMS**. The platform is designed to aid in the development of small-molecule drug compounds and predict their interactions with the human body. GEMS can make drug development faster and more efficient by modeling how these compounds can bind with flexible or slippery proteins.




This company's latest series B fundraising has raised nine figures, which is a significant increase from its previous fundraising of \$52 million in series A held in December 2020. The last round was led by Rock Springs Capital and supported by T. Rowe Price Associates, Menlo Ventures, Radical Ventures, and Andreessen Horowitz, who had previously backed the company's early seed funding.

The latest appeal from **Genesis** saw all of its previous backers return, alongside a16z Bio + Health and an unnamed U.S.-based life-sciences-focused investor who took up co-

Recent Posts

 Wand app has secured \$4.2 million in funding to expand its AI-powered tool for artists


 Arm gears up for the year biggest IPO with a valuation of 60 billion dollars

 Friend.tech attracts an impressive 100K users within days

 Microbiome startup Viome secures \$86.5M funding and teams up with CVS for distribution

 Plant-based protein producer Enough secures €40 million to meet soaring demand







**\$11.04 mil
milliones**




Figure 3. Q1 2024 funding in USD distributed by employee size ranges.




Figure 4. Q1 2024 funding in USD distributed by geographical region. EMEA (Europe, Middle-East, Africa), Asia-Pacific (APAC), and North America (NA).

● Device ● IVD/Diagnostic ● SaMD/DTx




Figure 6. Funding distribution by medical technology type. Device 71.8%, IVD/Diagnostic 26.2%, and SaMD/DTx 2%.

Medical Device Company Funding Distribution by Therapeutic Area




Figure 8. Medical device funding distribution by therapeutic area.

A close-up photograph of a doctor's hands holding an open book. The doctor is wearing a white lab coat, a patterned tie, and a stethoscope. The book has a red cover with the words "Clinical Trials" printed on it. A large white number "264" is overlaid on the left side of the book's cover. The right page of the book shows a grid with a dotted line graph.


264

Clinical Trials

Clinical Trials



Global new medical device clinical trials by market - June 2022







**¿DONDE HAY
PACIENTES?**













¿Qué buscan?





COOL

COOL





iViajemos!



Prague Cracow Lublin Lviv Dniester

ZECH REP. Vienna

SLOVAKIA Bratislava

AUSTRIA Graz

HUNGARY Budapest

ROMANIA Galati Bucharest

SLOVENIA Zagreb

CROATIA Sarajevo

BOSNIA SERBIA Belgrade

MOLDOVA Chisinau

BULGARIA Sofia Varna

Danube





PARAGUAY

○ Concepción

★ Asunción

○ Campo Grande

Paraná

○ Londrina

○ Santa Cruz de la Sierra

Sucre

Pilcomayo

○ Salta

San Chaco

rientes



VENEZUELA

GUYANA

COLOMBIA

Bogotá

Ibagué

Cali

Neiva

Pasto

Quito

ECUADOR

Maracaibo

Barquisimeto

San Cristóbal

Meta

Puerto Ayacucho

Orinoco

Boa Vista

Branco

Negro

Japurá

Putumayo

Tonantins

Juruá

Carauari

Purus

Barranquilla

Cartagena

Montería

Mec

Guaviare

de Malpelo
(Colombia)

Esmeraldas

Punta Gallinas

Maracay

Valencia


Cumana

Ciudad Bolívar

Georgetown

A man in a light blue suit and striped tie is shown from the chest down, holding a large stack of US dollar bills. He is standing in a city street with tall buildings in the background. The scene is brightly lit, suggesting daytime. The man's right hand is holding the top of the stack, while his left hand is at the bottom. The bills are fanned out, showing various denominations including \$100, \$50, and \$20 bills. The background features a mix of modern glass-fronted buildings and older brick structures. A traffic light and some street signs are visible in the distance.

\$170000







Press Release Events Email Alerts

View All

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 23, 2021

IRVINE, CA / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the world's leading experts in vascular and endovascular medicine.

Patients in the first-in-human study demonstrated significant improvement in all study endpoints including an aggregate 54% improvement in reflux (the



CS 88M

Human trial using the novel bioprosthetic VenoValve in patients with chronic venous insufficiency

[Jorge H. Ulloa, MD, FACS](#)   • [Marc Glickman, MD, FACS](#)

[Open Access](#) • Published: November 19, 2020 • DOI: <https://doi.org/10.1016/j.jvsv.2020.10.017> •



Abstract

Keywords

Methods

Results

Discussion

Abstract

Background

Chronic venous insufficiency (CVI) is a disease characterized by failure of the venous valves that allow blood from the lower limbs to return to the heart. The more severe types of CVI (C4b-C6 disease) significantly influence patients' quality of life (QOL). The treatment options for CVI of the deep system are limited



ReGelTec's HYDRAFIL Technology Selected as Best Abstract Presentation

Clinical studies show chronic low back pain decreased by more than 80% in 60 patients at three months

ReGelTec, Inc., announced that Dr. Douglas Beall won the award for Best Abstract at the American Society for Pain and Neuroscience annual meeting that just concluded in Miami, FL. Dr. Beall presented an interim analysis of clinical data from feasibility studies of the company's HYDRAFIL™ technology for the treatment chronic low back pain (CLBP) that included 3-month follow-up results on sixty patients.

Baltimore based ReGelTec is developing a percutaneous treatment for CLBP caused by degenerative disc disease (DDD), a widely prevalent condition affecting an estimated 9% of the worldwide population and costing upwards of \$100B in direct treatments and lost productivity in the United States alone.

To date, the company has conducted clinical studies in Barranquilla and Cali, Colombia, and in Calgary, Canada with 60 patients receiving HYDRAFIL™ injections. Patients have experienced profound relief in their back pain and related disability scores. At the three month follow up visit the average back pain score is reduced by 81%, from a baseline of 7.3 to a score of 1.4, and disability scores measured by Oswestry Disability Index (ODI) dropped by 90%, from a baseline of 58% to a score of 6%.

"The results we are seeing with HYDRAFIL to date are nothing short of astounding," said Douglas Beall, MD Interventional Radiologist





UNITED STATES
CUSTOM HOUSE



The "Exit"



M&A

Mergers And Acquisitions

3200

3200

2800


2500

4500

5000

U.S. Medical Device Outsourcing Market Size

The U.S. Medical Device Outsourcing Market is projected to see annualized growth, led by demand for more efficient manufacturing.



Source: Research and Markets

Leading Regulatory and Testing Outsourced Providers



NAMSA[®]



Source: Medical Product Outsourcing, ComplianceGate, and Dot Compliance

A close-up photograph of two hands, one on the left and one on the right, holding several white puzzle pieces. The hands are positioned as if they are about to fit the pieces together. The background is a soft, out-of-focus orange color. The text is overlaid on the image in a white, sans-serif font.

Colombia se conectó al ecosistema
global de innovación médica y se
convertirá en una sociedad de
conocimiento.

Julio G. Martinez-Clark | jmclark@bioaccessla.com | +1 (954) 903-7210